StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)

Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%

Amgen pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Amgen's pe ratio was 29.1× on Nov 11, 2026, against 26.7× a year earlier. Over the last 5 years it ranged from 15.0× to 57.4×, with a median of 24.3×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202629.1×+3.8
2025Dec 31, 202525.3×−8.0
2024Dec 31, 202433.3×+12.9
2023Dec 29, 202320.5×−0.6
2022Dec 30, 202221.0×+2.4
2021Dec 31, 202118.6×+0.8
2020Dec 31, 202017.9×−1.3
2019Dec 31, 201919.1×−33.5
2018Dec 31, 201852.6×+36.9
2017Dec 29, 201715.7×+1.1
2016Dec 30, 201614.6×−4.8
2015Dec 31, 201519.4×−5.7
2014Dec 31, 201425.1×+4.4
2013Dec 31, 201320.7×−0.7
2012Dec 31, 201221.3×+8.0
2011Dec 30, 201113.3×+1.5
2010Dec 31, 201011.9×−0.8
2009Dec 31, 200912.7×–

More Amgen figures

See a number that looks wrong?